MedMen Enterprises Inc. Logo

MedMen Enterprises Inc.

MMNFF

(0.8)
Stock Price

0,00 USD

-38.42% ROA

-46.51% ROE

-0.26x PER

Market Cap.

17.981.600,00 USD

309.9% DER

0% Yield

-76.65% NPM

MedMen Enterprises Inc. Stock Analysis

MedMen Enterprises Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MedMen Enterprises Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.2x), the stock offers substantial upside potential at a bargain price.

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-46.51%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-38.42%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The company has a high debt to equity ratio (310%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

MedMen Enterprises Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MedMen Enterprises Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

MedMen Enterprises Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MedMen Enterprises Inc. Revenue
Year Revenue Growth
2002 305.464
2003 0 0%
2004 30.105 100%
2005 19.341 -55.65%
2006 20.278 4.62%
2007 22.176 8.56%
2008 36.415 39.1%
2009 33.599 -8.38%
2010 18.141 -85.22%
2011 27.656 34.41%
2012 19.656 -40.7%
2013 24.924 21.13%
2014 20.644 -20.73%
2015 26.652 22.54%
2016 20.066 -32.82%
2017 2.671.812 99.25%
2018 39.783.102 93.28%
2019 129.963.405 69.39%
2020 157.112.281 17.28%
2021 145.065.771 -8.3%
2022 140.811.689 -3.02%
2023 108.898.680 -29.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MedMen Enterprises Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MedMen Enterprises Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 45.594 100%
2005 19.113 -138.54%
2006 9.366 -104.07%
2007 8.913 -5.09%
2008 11.109 19.78%
2009 41.730 73.38%
2010 41.691 -0.1%
2011 28.223 -47.72%
2012 53.703 47.45%
2013 236.992 77.34%
2014 133.035 -78.14%
2015 240.605 44.71%
2016 136.184 -76.68%
2017 14.138.166 99.04%
2018 98.180.978 85.6%
2019 234.649.949 58.16%
2020 200.273.872 -17.16%
2021 124.585.936 -60.75%
2022 108.724.757 -14.59%
2023 63.841.804 -70.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MedMen Enterprises Inc. EBITDA
Year EBITDA Growth
2002 -269.547
2003 -74.816 -260.28%
2004 -24.707 -202.83%
2005 -7.554 -227.1%
2006 219.043 103.45%
2007 2.448 -8847.83%
2008 15.949 84.65%
2009 -18.446 186.46%
2010 -32.882 43.9%
2011 -11.264 -191.91%
2012 -43.071 73.85%
2013 -219.850 80.41%
2014 -120.348 -82.68%
2015 -221.609 45.69%
2016 -124.006 -78.71%
2017 -13.221.387 99.06%
2018 -91.449.994 85.54%
2019 -198.751.834 53.99%
2020 -149.039.214 -33.36%
2021 -54.842.800 -171.76%
2022 -35.562.775 -54.21%
2023 -27.767.920 -28.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MedMen Enterprises Inc. Gross Profit
Year Gross Profit Growth
2002 -89.558
2003 0 0%
2004 10.808 100%
2005 11.559 6.51%
2006 12.084 4.34%
2007 11.361 -6.36%
2008 27.058 58.02%
2009 23.284 -16.21%
2010 8.809 -164.35%
2011 16.959 48.06%
2012 10.631 -59.52%
2013 17.142 37.98%
2014 12.687 -35.11%
2015 18.996 33.21%
2016 12.178 -55.98%
2017 868.135 98.6%
2018 13.850.225 93.73%
2019 60.877.707 77.25%
2020 58.120.974 -4.74%
2021 67.289.170 13.63%
2022 69.727.458 3.5%
2023 52.590.528 -32.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MedMen Enterprises Inc. Net Profit
Year Net Profit Growth
2002 -1.271.660
2003 -75.182 -1591.46%
2004 325.431 123.1%
2005 -24.718 1416.62%
2006 189.272 113.06%
2007 -28.930 754.24%
2008 -21.050 -37.44%
2009 -48.884 56.94%
2010 -68.809 28.96%
2011 -46.230 -48.84%
2012 -78.480 41.09%
2013 -249.923 68.6%
2014 -122.803 -103.51%
2015 -228.136 46.17%
2016 -124.141 -83.77%
2017 -15.418.308 99.19%
2018 -112.264.844 86.27%
2019 -277.046.611 59.48%
2020 -475.749.370 41.77%
2021 -145.445.431 -227.1%
2022 -165.554.955 12.15%
2023 -124.833.304 -32.62%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MedMen Enterprises Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -29
2003 -2 -2700%
2004 7 116.67%
2005 -1 0%
2006 4 100%
2007 -1 0%
2008 0 0%
2009 -1 100%
2010 -2 0%
2011 -1 0%
2012 -2 0%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 -26 100%
2018 -3 -1200%
2019 -3 0%
2020 -2 -100%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MedMen Enterprises Inc. Free Cashflow
Year Free Cashflow Growth
2002 -86.158
2003 0 0%
2004 -13.328 100%
2005 -12.495 -6.66%
2006 -24.611 49.23%
2007 17.583 239.97%
2008 13.612 -29.17%
2009 -14.905 191.32%
2010 -64.352 76.84%
2011 -14.307 -349.79%
2012 -22.626 36.76%
2013 -106.077 78.67%
2014 -143.547 26.1%
2015 -87.857 -63.39%
2016 -106.950 17.85%
2017 -28.377.310 99.62%
2018 -128.466.184 77.91%
2019 -364.152.889 64.72%
2020 -170.955.296 -113.01%
2021 -67.474.027 -153.36%
2022 -72.185.897 6.53%
2023 -13.000.836 -455.24%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MedMen Enterprises Inc. Operating Cashflow
Year Operating Cashflow Growth
2002 -86.158
2003 0 0%
2004 -3.249 100%
2005 -12.495 74.01%
2006 -24.611 49.23%
2007 17.583 239.97%
2008 13.612 -29.17%
2009 -14.905 191.32%
2010 -64.352 76.84%
2011 -14.307 -349.79%
2012 -22.626 36.76%
2013 -106.077 78.67%
2014 -143.547 26.1%
2015 -87.857 -63.39%
2016 -106.950 17.85%
2017 -18.152.351 99.41%
2018 -68.876.515 73.65%
2019 -236.099.863 70.83%
2020 -110.126.749 -114.39%
2021 -59.700.010 -84.47%
2022 -62.529.441 4.52%
2023 -14.838.878 -321.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MedMen Enterprises Inc. Capital Expenditure
Year Capital Expenditure Growth
2002 0
2003 0 0%
2004 10.079 100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 10.224.959 100%
2018 59.589.669 82.84%
2019 128.053.026 53.46%
2020 60.828.547 -110.51%
2021 7.774.017 -682.46%
2022 9.656.456 19.49%
2023 -1.838.042 625.37%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MedMen Enterprises Inc. Equity
Year Equity Growth
2002 -767.127
2003 -856.123 10.4%
2004 -685.627 -24.87%
2005 -767.811 10.7%
2006 -601.794 -27.59%
2007 -662.906 9.22%
2008 -803.441 17.49%
2009 -685.854 -17.14%
2010 -829.945 17.36%
2011 -927.044 10.47%
2012 -273.445 -239.02%
2013 -413.349 33.85%
2014 -1.899 -21666.61%
2015 361.215 100.53%
2016 191.455 -88.67%
2017 33.579.865 99.43%
2018 197.197.285 82.97%
2019 200.849.266 1.82%
2020 -176.888.450 213.55%
2021 -253.633.619 30.26%
2022 -318.512.736 20.37%
2023 -357.388.431 10.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MedMen Enterprises Inc. Assets
Year Assets Growth
2002 0
2003 2.870 100%
2004 883 -225.03%
2005 3.002 70.59%
2006 3.602 16.63%
2007 2.235 -61.12%
2008 2.769 19.26%
2009 16.748 83.47%
2010 12.066 -38.81%
2011 7.296 -65.39%
2012 780.269 99.07%
2013 29.063 -2584.84%
2014 37.034 21.53%
2015 372.187 90.05%
2016 200.633 -85.51%
2017 60.431.402 99.67%
2018 282.190.342 78.58%
2019 634.630.235 55.53%
2020 574.263.604 -10.51%
2021 472.463.690 -21.55%
2022 323.223.684 -46.17%
2023 215.587.114 -49.93%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MedMen Enterprises Inc. Liabilities
Year Liabilities Growth
2002 767.127
2003 858.994 10.69%
2004 686.511 -25.12%
2005 770.813 10.94%
2006 605.395 -27.32%
2007 665.141 8.98%
2008 806.209 17.5%
2009 702.602 -14.75%
2010 842.011 16.56%
2011 934.339 9.88%
2012 1.053.715 11.33%
2013 442.411 -138.18%
2014 38.934 -1036.34%
2015 10.973 -254.84%
2016 9.178 -19.56%
2017 26.851.537 99.97%
2018 84.993.057 68.41%
2019 433.780.969 80.41%
2020 751.152.054 42.25%
2021 726.097.309 -3.45%
2022 641.736.420 -13.15%
2023 572.975.545 -12%

MedMen Enterprises Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.06
Net Income per Share
-0.05
Price to Earning Ratio
-0.26x
Price To Sales Ratio
0.21x
POCF Ratio
-0.75
PFCF Ratio
-0.66
Price to Book Ratio
0.14
EV to Sales
4.49
EV Over EBITDA
-50.3
EV to Operating CashFlow
-16.81
EV to FreeCashFlow
-14.25
Earnings Yield
-3.82
FreeCashFlow Yield
-1.52
Market Cap
0,02 Bil.
Enterprise Value
0,39 Bil.
Graham Number
0.32
Graham NetNet
-0.41

Income Statement Metrics

Net Income per Share
-0.05
Income Quality
0.33
ROE
-0.47
Return On Assets
-0.31
Return On Capital Employed
0.07
Net Income per EBT
0.97
EBT Per Ebit
3.7
Ebit per Revenue
-0.21
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
0.56
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.5
Operating Profit Margin
-0.21
Pretax Profit Margin
-0.79
Net Profit Margin
-0.77

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
0.18
Capex to Revenue
-0.05
Capex to Depreciation
-0.39
Return on Invested Capital
-0.03
Return on Tangible Assets
-0.38
Days Sales Outstanding
16.24
Days Payables Outstanding
161.66
Days of Inventory on Hand
122.33
Receivables Turnover
22.48
Payables Turnover
2.26
Inventory Turnover
2.98
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,09
Tangible Book Value per Share
-0.3
Shareholders Equity per Share
0.09
Interest Debt per Share
0.31
Debt to Equity
3.1
Debt to Assets
1.76
Net Debt to EBITDA
-47.98
Current Ratio
0.19
Tangible Asset Value
-0,40 Bil.
Net Current Asset Value
-0,48 Bil.
Invested Capital
3.1
Working Capital
-0,38 Bil.
Intangibles to Total Assets
0.2
Average Receivables
0,01 Bil.
Average Payables
0,02 Bil.
Average Inventory
14171949.5
Debt to Market Cap
21.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MedMen Enterprises Inc. Dividends
Year Dividends Growth

MedMen Enterprises Inc. Profile

About MedMen Enterprises Inc.

MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.

CEO
Mr. Amit Pandey
Employee
428
Address
10115 Jefferson Boulevard
Culver City, 90232

MedMen Enterprises Inc. Executives & BODs

MedMen Enterprises Inc. Executives & BODs
# Name Age
1 Karen Torres
Chief Supply Chain Officer
70
2 Kimble Cannon
General Counsel & Corporate Secretary
70
3 Richard Ormond
Chief Restructuring Officer
70
4 Mr. Amit Pandey
Chief Financial Officer
70
5 Ms. Stéphanie Van Hassel
Vice President of Investor Relations
70

MedMen Enterprises Inc. Competitors